Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu 5)

Journal of Medicinal Chemistry

Volumn 57, Issue 13, 2014, Pages 5620-5637

  Turlington, Mark ^a,b   Malosh, Chrysa ^a,b   Jacobs, Jon ^a,b   Manka, Jason T ^a,b   Noetzel, Meredith J ^a,b   Vinson, Paige N ^a,b   Jadhav, Satyawan ^a,b   Herman, Elizabeth J ^a,b   Lavreysen, Hilde ^d   Mackie, Claire ^d   Bartolomé Nebreda, José M ^d   Conde Ceide, Susana ^d   Martín Martín, M Luz ^d   Tong, Han Min ^d   López, Silvia ^d   Macdonald, Gregor J ^d   Steckler, Thomas ^d   Daniels, J Scott ^a,b   Weaver, C David ^a   Niswender, Colleen M ^a,b   Jones, Carrie K ^a,b   Conn, P Jeffrey ^a,b   Lindsley, Craig W ^a,b,c   Stauffer, Shaun R ^a,b,c   more..

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

(4 FLUOROPHENYL)(3 (PHENOXYMETHYL) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 6(5H) YL)METHANONE; 2 ((3 FLUOROBENZYL)OXY) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6H) ONE; 2 ((3 FLUOROPHENOXY)METHYL) 6 (5 FLUOROPYRIDIN 2 YL) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6H) ONE; 2 ((3 FLUOROPHENOXY)METHYL) 6 ISOBUTYL 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6H) ONE; 2 ((3 FLUOROPHENOXY)METHYL) 6 METHYL 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6H) ONE; 2 ((3 FLUOROPHENOXY)METHYL) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 2 5(6H) ONE; 2 (4 FLUOROPHENYL) 6 PHENOXYMETHYL 3,4 DIHYDRO 2H [2,7]NAPHTHYRIDIN 1 ONE; 2 (BENZYLOXY) 6 (PYRIDIN 2 YLMETHYL) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6H) ONE; 2 (BENZYLOXY) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6H) ONE; 2 BUTOXY 6 (2,4 DIFLUOROPHENYL) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6) ONE; 2 BUTOXY 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6H) ONE; 2 METHYL 6 PHENOXYMETHYL 3,4 DIIHYDRO 2H [2,7]NAPHTHYRIDIN 1 ONE; 3 PHENOXYMETHYL 6,7 DIHYDRO 5H [1,7]NAPHTHYRIDIN 8 ONE; 3 PHENOXYMETHYL 7 (1,2,2 TRIMETHYL PROPYL) 6,7 DIHYDRO 5H [1,7]NAPHTHYRIDIN 8 ONE; 6 (4 FLUOROPHENYL) 2 (PHENOXYMETHYL) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6H) ONE; 6 (CYCLOPROPYLMETHYL) 2 ((3 FLUOROPHENOXY)METHYL) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6H) ONE; 6 BENZYL 2 ((3 FLUOROPHENOXY)METHYL) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6H) ONE; 6 BENZYL 2 (BENZYLOXY) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 5(6H) ONE; 6 PHENOXYMETHYL 2 (1,2,2 TRIMETHYL PROPYL) 3,4 DIHYDRO 2H [2,7]NAPHTHYRIDIN 1 ONE; 6 PHENOXYMETHYL 3,4 DIHYDRO 2H [2,7]NAPHTHYRIDIN 1 ONE; 7 (4 FLUOROPHENYL) 3 PHENOXYMETHYL 6,7 DIHYDRO 5H [1,7]NAPHTHYRIDIN 8 ONE; 7 METHYL 3 (PHENOXYMETHYL) 6,7 DIHYDRO 1,7 NAPHTHYRIDIN 8(5H) ONE; ACETYLENE; AMIDE; CYCLOPROPYL(3 ((3 FLUOROBENZYL)OXY) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 6(5H) YL)METHANONE; ETHER DERIVATIVE; METABOTROPIC RECEPTOR 5; NAPHTHYRIDINE DERIVATIVE; PYRIDINE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHEMICAL STRUCTURE; DRUG CLEARANCE; DRUG POTENCY; DRUG STRUCTURE; IN VITRO STUDY; ISOMER; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CLEARANCE; RAT; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; HEK293 CELLS; HUMANS; MICROSOMES, LIVER; NAPHTHYRIDINES; RATS; RECEPTOR, METABOTROPIC GLUTAMATE 5; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904280444     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500259z     Document Type: Article

References (62)

1. Meltzer, H. Y. Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions Biol. Psychiatry 1999, 46, 1321-1327
2. Lewis, D. A.; Lieberman, J. A. Catching up on schizophrenia: natural history and neurobiology Neuron 2000, 28, 325-334
3. Lieberman, J. A.; Stroup, T. S.; McEvoy, J. P.; Swartz, M. S.; Rosenheck, R. A.; Perkins, D. O.; Keefe, R. S.; Davis, S. M.; Davis, C. E.; Lebowitz, B. D.; Severe, J.; Hsiao, J. K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N. Engl. J. Med. 2005, 353, 1209-1223 (Pubitemid 41345943)
4. Nuechterlein, K. H.; Barch, D. M.; Gold, J. M.; Goldberg, T. E.; Green, M. F.; Heaton, R. K. Identification of separable cognitive factors in schizophrenia Schizophrenia Res. 2004, 72, 29-39 (Pubitemid 39452903)
5. Toda, M.; Abi-Dargham, A. Dopamine hypothesis of schizophrenia: making sense of it all Curr. Psychiatry Rep. 2007, 9, 329-936
6. Meltzer, H. Y. Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial J. Clin. Psychiatry 1999, 60 (Suppl 12) 47-50 (Pubitemid 29283184)
7. Ray, W. A.; Chung, C. P.; Murray, K. T.; Hall, K.; Stein, C. M. Atypical antipsychotic drugs and the risk of sudden cardiac death N. Engl. J. Med. 2009, 360, 225-235
8. Bordi, F.; Ugolini, A. Group I metabotropic glutamate receptors: implications for brain diseases Prog. Neurobiol. 1999, 59, 55-79 (Pubitemid 29274422)
9. Conn, P. J.; Lindsley, C. W.; Jones, C. K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 2009, 30, 25-31
10. Chavez-Noriega, L. E.; Schaffhauser, H.; Campbell, U. C. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia Curr. Drug Targets: CNS Neurol. Disord. 2002, 1, 261-281
11. Perroy, J.; Raynaud, F.; Homburger, V.; Rousset, M. C.; Telley, L.; Bockaert, J.; Fagni, L. Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors J. Biol. Chem. 2008, 283, 6799-6805
12. Williams, D. L., Jr.; Lindsley, C. W. Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5) Curr. Top. Med. Chem. 2005, 5, 825-846 (Pubitemid 41269558)
13. Shipe, W. D.; Wolkenberg, S. E.; Williams, D. L., Jr.; Lindsley, C. W. Recent advances in positive allosteric modulators of metabotropic glutamate receptors Curr. Opin. Drug Discovery Dev. 2005, 8, 449-457 (Pubitemid 40917406)
14. Marino, M. J.; Conn, P. J. Direct and indirect modulation of the N -methyl d -aspartate receptor Curr. Drug Targets: CNS Neurol. Disord. 2002, 1, 1-16
15. Stauffer, S. R. Progress toward positive allosteric modulators of the metabotropic glutamate receptor rubtype 5 (mGlu5) ACS Chem. Neurosci. 2011, 2, 450-470
16. Lindsley, C. W.; Stauffer, S. R. Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012) Pharm. Pat. Analyst 2013, 2, 93-108
17. Kinney, G. G.; O'Brien, J. A.; Lemaire, W.; Burno, M.; Bickel, D. J.; Clements, M. K.; Chen, T. B.; Wisnoski, D. D.; Lindsley, C. W.; Tiller, P. R.; Smith, S.; Jacobson, M. A.; Sur, C.; Duggan, M. E.; Pettibone, D. J.; Conn, P. J.; Williams, D. L., Jr. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J. Pharmacol. Exp. Ther. 2005, 313, 199-206 (Pubitemid 40411343)
18. Le Poul, E.; Bessis, A. S.; Lutgens, R.; Bonnet, B.; Rocher, J. P.; Epping-Jordan, M. P.; Mutel, V. In vitro pharmacological characterization of selective mGluR5 positive allosteric modulators. 5th International Metabotropic Glutamate Receptors Meeting, Taormina, Italy, 2005.
19. Bessis, A.-S.; Bonnet, B.; Le, P. E.; Rocher, J.-P.; Epping-Jordan, M. Preparation of piperidine derivatives as modulators of metabotropic glutamate receptors (mGluR5). WO 2005044797, 2005.
20. Sharma, S.; Kedrowski, J.; Rook, J. M.; Smith, R. L.; Jones, C. K.; Rodriguez, A. L.; Conn, P. J.; Lindsley, C. W. Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines J. Med. Chem. 2009, 52, 4103-4106
21. Rodriguez, A. L.; Grier, M. D.; Jones, C. K.; Herman, E. J.; Kane, A. S.; Smith, R. L.; Williams, R.; Zhou, Y.; Marlo, J. E.; Days, E. L.; Blatt, T. N.; Jadhav, S.; Menon, U. N.; Vinson, P. N.; Rook, J. M.; Stauffer, S. R.; Niswender, C. M.; Lindsley, C. W.; Weaver, C. D.; Conn, P. J. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity Mol. Pharmacol. 2010, 78, 1105-1123
22. Gastambide, F.; Cotel, M. C.; Gilmour, G.; O'Neill, M. J.; Robbins, T. W.; Tricklebank, M. D. Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator Neuropsychopharmacology 2012, 37, 1057-1066
23. Gilmour, G.; Broad, L. M.; Wafford, K. A.; Britton, T.; Colvin, E. M.; Fivush, A.; Gastambide, F.; Getman, B.; Heinz, B. A.; McCarthy, A. P.; Prieto, L.; Shanks, E.; Smith, J. W.; Taboada, L.; Edgar, D. M.; Tricklebank, M. D. In vitro characterisation of the novel positive allosteric modulators of the mGlu(5) receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat Neuropharmacology 2013, 64, 224-239
24. Zhou, Y.; Manka, J. T.; Rodriguez, A. L.; Weaver, C. D.; Days, E. L.; Vinson, P. N.; Jadhav, S.; Hermann, E. J.; Jones, C. K.; Conn, P. J.; Lindsley, C. W.; Stauffer, S. R. Discovery of N -aryl piperazines as selective mGluR5 potentiators with improved in vivo utility ACS Med. Chem. Lett. 2010, 1, 433-438
25. Spear, N.; Gadient, R. A.; Wilkins, D. E.; Do, M.; Smith, J. S.; Zeller, K. L.; Schroeder, P.; Zhang, M.; Arora, J.; Chhajlani, V. Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator Eur. J. Pharmacol. 2011, 659, 146-154
26. Manka, J. T.; Vinson, P. N.; Gregory, K. J.; Zhou, Y.; Williams, R.; Gogi, K.; Days, E.; Jadhav, S.; Herman, E. J.; Lavreysen, H.; Mackie, C.; Bartolome, J. M.; Macdonald, G. J.; Steckler, T.; Daniels, J. S.; Weaver, C. D.; Niswender, C. M.; Jones, C. K.; Conn, P. J.; Lindsley, C. W.; Stauffer, S. R. Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover Bioorg. Med. Chem. Lett. 2012, 22, 6481-6185
27. Parmentier-Batteur, S.; Obrien, J. A.; Doran, S.; Nguyen, S. J.; Flick, R. B.; Uslaner, J. M.; Chen, H.; Finger, E. N.; Williams, T. M.; Jacobson, M. A.; Hutson, P. H. Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration Neuropharmacology 2012, 62, 1453-1460
28. Rook, J. M.; Noetzel, M. J.; Pouliot, W. A.; Bridges, T. M.; Vinson, P. N.; Cho, H. P.; Zhou, Y.; Gogliotti, R. D.; Manka, J. T.; Gregory, K. J.; Stauffer, S. R.; Dudek, F. E.; Xiang, Z.; Niswender, C. M.; Daniels, J. S.; Jones, C. K.; Lindsley, C. W.; Conn, P. J. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity Biol. Psychiatry 2013, 73, 501-509
29. Bridges, T. M.; Rook, J. M.; Noetzel, M. J.; Morrison, R. D.; Zhou, Y.; Gogliotti, R. D.; Vinson, P. N.; Xiang, Z.; Jones, C. K.; Niswender, C. M.; Lindsley, C. W.; Stauffer, S. R.; Conn, P. J.; Daniels, J. S. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism Drug Metab. Dispos. 2013, 41, 1703-1714
30. Turlington, M.; Noetzel, M. J.; Chun, A.; Zhou, Y.; Gogliotti, R. D.; Nguyen, E. D.; Gregory, K. J.; Vinson, P. N.; Rook, J. M.; Gogi, K. K.; Xiang, Z.; Bridges, T. M.; Daniels, J. S.; Jones, C.; Niswender, C. M.; Meiler, J.; Conn, P. J.; Lindsley, C. W.; Stauffer, S. R. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu) positive allosteric modulators (PAMs): discovery of 5-((3-Fluorophenyl)ethynyl)- N -(3-methyloxetan-3-yl)picolinamide (ML254) J. Med. Chem. 2013, 56, 7976-7996
31. Bartolome-Nebreda, J. M.; Conde-Ceide, S.; Delgado, F.; Iturrino, L.; Pastor, J.; Pena, M. A.; Trabanco, A. A.; Tresadern, G.; Wassvik, C. M.; Stauffer, S. R.; Jadhav, S.; Gogi, K.; Vinson, P. N.; Noetzel, M. J.; Days, E.; Weaver, C. D.; Lindsley, C. W.; Niswender, C. M.; Jones, C. K.; Conn, P. J.; Rombouts, F.; Lavreysen, H.; Macdonald, G. J.; Mackie, C.; Steckler, T. Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor J. Med. Chem. 2013, 56, 7243-7259
32. Williams, R.; Manka, J. T.; Rodriguez, A. L.; Vinson, P. N.; Niswender, C. M.; Weaver, C. D.; Jones, C. K.; Conn, P. J.; Lindsley, C. W.; Stauffer, S. R. Synthesis and SAR of centrally active mGlu(5) positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold Bioorg. Med. Chem. Lett. 2011, 21, 1350-1353
33. Wood, M. R.; Hopkins, C. R.; Brogan, J. T.; Conn, P. J.; Lindsley, C. W. "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology Biochemistry 2011, 50, 2403-2410
34. Engers, D. W.; Rodriguez, A. L.; Williams, R.; Hammond, A. S.; Venable, D.; Oluwatola, O.; Sulikowski, G. A.; Conn, P. J.; Lindsley, C. W. Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273 ChemMedChem 2009, 4, 505-511
35. Lamb, J. P.; Engers, D. W.; Niswender, C. M.; Rodriguez, A. L.; Venable, D. F.; Conn, J. P.; Lindsley, C. W. Discovery of molecular switches within the ADX-47273 mGlu(5) PAM scaffold that modulate modes of pharmacology to afford potent mGlu(5) NAMs, PAMs and partial antagonists Bioorg. Med. Chem. Lett. 2011, 21, 2711-2714
36. Lindsley, C. W.; Wisnoski, D. D.; Leister, W. H.; O'Brien, J. A.; Lemaire, W.; Williams, D. L., Jr.; Burno, M.; Sur, C.; Kinney, G. G.; Pettibone, D. J.; Tiller, P. R.; Smith, S.; Duggan, M. E.; Hartman, G. D.; Conn, P. J.; Huff, J. R. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N -(1,3-diphenyl-1 H -pyrazol-5-yl)benzamides that potentiate receptor function in vivo J. Med. Chem. 2004, 47, 5825-5828 (Pubitemid 39507327)
37. de Paulis, T.; Hemstapat, K.; Chen, Y.; Zhang, Y.; Saleh, S.; Alagille, D.; Baldwin, R. M.; Tamagnan, G. D.; Conn, P. J. Substituent effects of N -(1,3-diphenyl-1 H -pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes J. Med. Chem. 2006, 49, 3332-3344 (Pubitemid 43830531)
38. O'Brien, J. A.; Lemaire, W.; Wittmann, M.; Jacobson, M. A.; Ha, S. N.; Wisnoski, D. D.; Lindsley, C. W.; Schaffhauser, H. J.; Rowe, B.; Sur, C.; Duggan, M. E.; Pettibone, D. J.; Conn, P. J.; Williams, D. L., Jr. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain J. Pharmacol. Exp. Ther. 2004, 309, 568-577 (Pubitemid 38542609)
39. Zhao, Z.; Wisnoski, D. D.; O'Brien, J. A.; Lemaire, W.; Williams, D. L., Jr.; Jacobson, M. A.; Wittman, M.; Ha, S. N.; Schaffhauser, H.; Sur, C.; Pettibone, D. J.; Duggan, M. E.; Conn, P. J.; Hartman, G. D.; Lindsley, C. W. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA Bioorg. Med. Chem. Lett. 2007, 17, 1386-1391 (Pubitemid 46240838)
40. Noetzel, M. J.; Gregory, K. J.; Vinson, P. N.; Manka, J. T.; Stauffer, S. R.; Lindsley, C. W.; Niswender, C. M.; Xiang, Z.; Conn, P. J. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling Mol. Pharmacol. 2013, 83, 835-847
41. Xiong, H.; Brugel, T. A.; Balestra, M.; Brown, D. G.; Brush, K. A.; Hightower, C.; Hinkley, L.; Hoesch, V.; Kang, J.; Koether, G. M.; McCauley, J. P., Jr.; McLaren, F. M.; Panko, L. M.; Simpson, T. R.; Smith, R. W.; Woods, J. M.; Brockel, B.; Chhajlani, V.; Gadient, R. A.; Spear, N.; Sygowski, L. A.; Zhang, M.; Arora, J.; Breysse, N.; Wilson, J. M.; Isaac, M.; Slassi, A.; King, M. M. 4-Aryl piperazine and piperidine amides as novel mGluR5 positive allosteric modulators Bioorg. Med. Chem. Lett. 2010, 20, 7381-7384
42. Rodriguez, A. L.; Zhou, Y.; Williams, R.; David Weaver, C.; Vinson, P. N.; Dawson, E. S.; Steckler, T.; Lavreysen, H.; Mackie, C.; Bartolome, J. M.; Macdonald, G. J.; Scott Daniels, J.; Niswender, C. M.; Jones, C. K.; Jeffrey Conn, P.; Lindsley, C. W.; Stauffer, S. R. Discovery and SAR of a novel series of non-MPEP site mGlu(5) PAMs based on an aryl glycine sulfonamide scaffold Bioorg. Med. Chem. Lett. 2012, 22, 7388-7392
43. Conn, J. P.; Lindsley, C. W.; Stauffer, S. R.; Manka, J.; Jacobs, J.; Zhou, Y.; Bartolome, J. M.; Macdonald, G. J.; Conde-Ceide, S.; Jones, C. K. Preparation of naphthyridinone analogs as mGluR5 positive allosteric modulators. WO2012092530, 2012.
44. Conn, J. P.; Lindsley, C. W.; Stauffer, S. R.; Manka, J.; Jacobs, J.; Zhou, Y.; Bartolome, J. M.; Macdonald, G. J.; Conde-Ceide, S.; Dawson, E. Preparation of dihydronaphthyridinyl(organo)methanone analogs as positive allosteric mGluR5 modulators for the treatment of neurologic and psychiatric disorders. U.S. Pat. Appl. 20120178776, 2012.
45. Manka, J.; Jacobs, J.; Zhou, Y.; Vinson, P. N.; Jadhav, S.; Herman, E. J.; Lavreysen, H.; Mackie, C.; Bartolome, J. M.; Macdonald, G. J.; Steckler, T.; Daniels, J. S.; Weaver, C.; Niswender, C. M.; Jones, C.; Conn, J. P.; Lindsley, C. W.; Stauffer, S. R. Bicyclic tetrahydronaphthridine and dihydronaphthridinone ethers as positive allosteric modulators of mGlu5. Presented at the 244th ACS National Meeting, Philadelphia, Aug 19-23, 2012, Poster MEDI 190.
46. Noetzel, M. J.; Rook, J. M.; Vinson, P. N.; Cho, H. P.; Days, E.; Zhou, Y.; Rodriguez, A. L.; Lavreysen, H.; Stauffer, S. R.; Niswender, C. M.; Xiang, Z.; Daniels, J. S.; Jones, C. K.; Lindsley, C. W.; Weaver, C. D.; Conn, P. J. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function Mol. Pharmacol. 2012, 81, 120-133
47. Hammond, A. S.; Rodriguez, A. L.; Townsend, S. D.; Niswender, C. M.; Gregory, K. J.; Lindsley, C. W.; Conn, P. J. Discovery of a novel chemical class of mGlu(5) allosteric ligands with distinct modes of pharmacology ACS Chem. Neurosci. 2010, 1, 702-716
48. Varnes, J. G.; Marcus, A. P.; Mauger, R. C.; Throner, S. R.; Hoesch, V.; King, M. M.; Wang, X.; Sygowski, L. A.; Spear, N.; Gadient, R.; Brown, D. G.; Campbell, J. B. Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu(5) Bioorg. Med. Chem. Lett. 2011, 21, 1402-1406
49. Conn, J. P.; Lindsley, C. W.; Stauffer, S. R.; Zhou, Y.; Macdonald, G.; Bartolome, J. M. Substituted-6-methylnicotinamides as mGluR5 positive allosteric modulators. WO2011149963, 2011.
50. Conn, J. P.; Lindsley, C. W.; Weaver, C. D.; Stauffer, S.; Williams, R.; McDonald, G.; Bartolome-Nebreda, J. M.; Zhou, Y. Preparation of O -benzyl nicotinamide analogs as mGluR5 positive allosteric modulators. WO2011035324, 2011.
51. Kubas, H.; Meyer, U.; Krueger, B.; Hechenberger, M.; Vanejevs, M.; Zemribo, R.; Kauss, V.; Ambartsumova, R.; Pyatkin, I.; Polosukhin, A. I.; Abel, U. Discovery, synthesis, and structure-activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators Bioorg. Med. Chem. Lett. 2013, 23, 4493-4500
52. Liu, F.; Grauer, S.; Kelley, C.; Navarra, R.; Graf, R.; Zhang, G.; Atkinson, P. J.; Popiolek, M.; Wantuch, C.; Khawaja, X.; Smith, D.; Olsen, M.; Kouranova, E.; Lai, M.; Pruthi, F.; Pulicicchio, C.; Day, M.; Gilbert, A.; Pausch, M. H.; Brandon, N. J.; Beyer, C. E.; Comery, T. A.; Logue, S.; Rosenzweig-Lipson, S.; Marquis, K. L. ADX-47273 [ S -(4-fluoro-phenyl)-{3-[3-(4- fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piper idin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities J. Pharmacol. Exp. Ther. 2008, 327, 827-839
53. Lindsley, C. W.; Stauffer, S. R. Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012) Pharm. Pat. Anal. 2013, 2, 93-108
54. Rook, J. M.; Vinson, P. N.; Bridges, T. M.; Stauffer, S. R.; Ghoshal, A.; Daniels, J. S.; Niswender, C. M.; Lavreysen, H.; Mackie, C.; Bartolome, J. M.; Macdonald, G. J.; Steckler, T.; Jones, C. K.; Lindsley, C. W.; Conn, J. P. Discovery of Metabotropic Glutamate Receptor Subtype 5 PAMs that Display Stimulus Bias Reveals that in Vivo Efficacy in Animal Models can be Achieved Without Direct Potentiation of NMDAR Currents. Presented at ACNP 52nd Annual Meeting, Hollywood, FL, Dec. 8-12, 2013, Poster W203.
55. Jain, A. N. Virtual screening in lead discovery and optimization Curr. Opin. Drug Discovery Dev. 2004, 7, 396-403
56. Jain, A. N. Ligand-based structural hypotheses for virtual screening J. Med. Chem. 2004, 47, 947-961 (Pubitemid 38176797)
57. Rodriguez, A. L.; Nong, Y.; Sekaran, N. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. J. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators Mol. Pharmacol. 2005, 68, 1793-1802 (Pubitemid 41654362)
58. Keseru, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates Nature Rev. Drug Discovery 2009, 8, 203-212
59. Shultz, M. D. The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations Bioorg. Med. Chem. Lett. 2013, 23, 5992-6000
60. Gregory, K. J.; Noetzel, M. J.; Rook, J. M.; Vinson, P. N.; Stauffer, S. R.; Rodriguez, A. L.; Emmitte, K. A.; Zhou, Y.; Chun, A. C.; Felts, A. S.; Chauder, B. A.; Lindsley, C. W.; Niswender, C. M.; Conn, P. J. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships Mol. Pharmacol. 2012, 82, 860-875
61. Di, L.; Rong, H.; Feng, B. Demystifying brain penetration in central nervous system drug discovery. Miniperspective J. Med. Chem. 2013, 56, 2-12
62. Niswender, C. M.; Johnson, K. A.; Luo, Q.; Ayala, J. E.; Kim, C.; Conn, P. J.; Weaver, C. D. A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors Mol. Pharmacol. 2008, 73, 1213-1224 (Pubitemid 351439203)